Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record.

A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)

Hecht, J. R., Trarbach, T., Jaeger, E., Hainsworth, J., Wolff, R., Lloyd, K., Bodoky, G., Borner, M., Laurent, D., Jacques, C. · 2005 · Journal of Clinical Oncology

Abstract

LBA3 Background: PTK787/ZK 222584 (PTK/ZK) is a novel, oral, small molecule, anti-angiogenesis compound that blocks tyrosine kinase signaling from all known vascular endothelial growth factor (VEGF) receptors. Phase I/II studies of PTK/ZK as a single agent showed that it is safe and well tolerated. Dose response was observed by DCE-MRI. An expanded phase I/II study evaluating escalating doses of PTK/ZK in combination with oxaliplatin/5-FU/LV as first-line therapy of metastatic colorectal cancer (CRC) demonstrated that chemotherapy and PTK/ZK could be safely administered as combination therapy. An overall response rate of 49% was observed; an additional 44% of Pts achieved stable disease. Methods: A multinational, randomized double-blind, placebo controlled phase III study has recently been completed to evaluate PTK/ZK in combination with the FOLFOX-4 regimen (oxaliplatin/5-FU/LV) in Pts with metastatic adenocarcinoma of the colon or rectum. Pts were included if they had histologically documented metastatic CRC, the presence of measurable disease, WHO Performance Status of 0–2 and adequate organ and bone marrow function. Pts were stratified in a 1:1 randomization scheme to receive oxaliplatin/5-FU/LV every 2 weeks according to the FOLFOX-4 regimen (de Gramont 2000) with either placebo or PTK/ZK given at a dose of 1250 mg, administered on a once-daily continuous schedule. Adjuvant therapy for primary CRC was acceptable providing that at least 6 months had elapsed from the conclusion of therapy to the time disease recurrence was documented. The primary endpoint was progression free survival (PFS). The study was designed to have at least 90% power to detect an increase in median PFS from approximately 9 months to 12 months at 5% significance level (two-sided). PFS data for the two treatment arms will be compared using a stratified log-rank test. Results: A total of 1168 Pts were randomized. Data for the primary endpoint (PFS) and secondary endpoints (overall response rate, time to progression, safety) will be presented for both treatment groups. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis, Schering AG Novartis

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.23.16_suppl.lba3

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 201

Metadata

Authors
Hecht, J. R., Trarbach, T., Jaeger, E., Hainsworth, J., Wolff, R., Lloyd, K., Bodoky, G., Borner, M., Laurent, D., & Jacques, C.
Venue
Journal of Clinical Oncology
Published
2005-06
Volume
23
Issue
16_suppl
Pages
LBA3-LBA3
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2244100803
Cited by
201
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). https://app.cochat.ai/papers/10.1200/jco.2005.23.16_suppl.lba3
The paper
Hecht, J. R., Trarbach, T., Jaeger, E., Hainsworth, J., Wolff, R., Lloyd, K., Bodoky, G., Borner, M., Laurent, D., & Jacques, C. (2005). A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.23.16_suppl.lba3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.